[Effect of inhalation therapy with beclomethasone dipropionate on unspecific bronchial hyperreactivity in patients with asthma].
An effect of beclomethasone dipropionate (Beclocort-Polfa) was investigated in the group of 24 patients with atopic and non-atopic bronchial asthma who have shown unspecific bronchial hyperreactivity to histamine during the periods of remission. The drug was administered in the form of aerosol in a daily dose of 1.0 mg for 4 weeks. Provocative histamine dose was established with Bronchoscreen device (Jaeger) thrice:prior to the treatment, after 1 week of placebo therapy, and after 1 month of beclomethasone administration. Statistically significant increase in histamine dose for provocation of bronchospasm (p < 0.01) being nearly twice higher than the baseline value has been noted in patients treated with beclomethasone dipropionate aerosol. It advocates such a treatment in unspecific bronchial hyperreactivity independently of the type of the bronchial asthma.
Jahnz-Rózyk
K
K
II Kliniki Instytutu Medycyny Wewnetrznej Centralnego Szpitala Klinicznego WAM, Warszawie.
Frank-Piskorska
A
A
Kozak
E
E
D000328:Adult; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D001507:Beclomethasone / Q000627:therapeutic use*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy*; D001985:Bronchial Provocation Tests; D005260:Female; D006632:Histamine; D006801:Humans; D008297:Male
D006632:Histamine; D001507:Beclomethasone
Wpływ wziewnego leczenia dwupropionianem beklometazonu na nieswoista nadreaktywność oskrzeli u chorych na dychawice.